Compare General Dynamics Corporation (GD) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Gilead Sciences, Inc. — how do they compare? General Dynamics Corporation trades at $331.32 (market cap $88.37B), while Gilead Sciences, Inc. trades at $147 (market cap $182.09B). The key difference: Gilead Sciences, Inc. is far larger — about 2.1× General Dynamics Corporation's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 85 Days and Gilead Sciences, Inc. for 111 Days on average.
| GD | GILD | |
|---|---|---|
Market Cap | $88.37B | $182.09B |
Volume | 1,251,409 | 4,960,247 |
Sector | Industrials | Health |
52-Week High | $395.97 | $155.80 |
52-Week Low | $312.53 | $116.74 |
Typical Hold Time | 85 Days | 111 Days |
Enterprise Value | $93.52B | $205.15B |
Dividend Yield | 1.95% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $329.90, down 0.43% with bearish technical signals despite strong fundamentals. The defense contractor shows consistent revenue growth to $52.55B in 2025 and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains strongly bullish with a $420.57 price target, while technical indicators show oversold conditions with RSI at 11.03.
GD offers solid value with reasonable valuation multiples and strong defense contract visibility, though near-term technical weakness and dependence on government spending create volatility. The stock's 27% upside to consensus target and consistent dividend payments provide attractive total return potential for long-term investors.
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
